GSK-4112 is an experimental drug that was developed by GlaxoSmithKline as an agonist of Rev-ErbAα.

[1] It is used for studying regulation of the circadian rhythm and its influence on diverse processes such as adipogenesis,[2][3] regulation of bone density,[4] and inflammation.

[5][6][7][8] This pharmacology-related article is a stub.

You can help Wikipedia by expanding it.